Chardan Capital Maintains Buy Rating on Gossamer Bio, Keeps $160 Target
Chardan Capital maintained its Buy rating and $160 price target on Gossamer Bio. The target implies 1,696.7% upside from the Oct. 14 close of $8.90.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.